CDMO（受託開発・製造機関）の日本市場規模、シェア、動向分析レポート：製品別、ワークフロー別、用途別、セグメント別予測、2023年～2030年

日本のCDMO（受託開発・製造機関）市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、日本のCDMO（受託開発・製造機関）市場規模は、2023年から2030年にかけてCAGR 5.9%を記録し、2030年までに195億米ドルに達する見込みです。

この市場の主な促進要因は、能力拡張のためのCDMO（受託開発・製造機関）（CDMO）による投資の増加、日本における高い高齢者人口と疾病負担の増大、医薬品製造・開発サービスのアウトソーシングに関連するコストの低さです。

COVID-19の大流行はCDMO市場の需要を押し上げました。日本のいくつかのCDMOはパンデミックの最中でも施設を拡張することで能力を向上させようとしていました。例えば、武州製薬は2020年8月に三郷工場の施設を拡張し、温度管理された無菌医薬品と生物製剤の保管専用施設としました。同様に、シミックグループは2020年7月、抗体医薬品の加工開発とGMP製造に特化した施設を日本に新設しました。国内のCDMOによるこうした取り組みは、市場に好影響を与えると予想されます。

市場参入企業は、施設の拡張、提携、パートナーシップ、新サービスの開始、M&Aなど、主要な戦略的取り組みに継続的に取り組んでいます。例えば、2020年5月、臨床供給サービス市場のリーダーであるキャタレント社は、テバ武田薬品工業（愛知県名古屋市）から臨床包装施設を買収する計画を発表しました。この買収により、臨床研究を支援するための新たな臨床GMP製造・流通拠点が構築されます。さらに2022年7月、キャタレント社は滋賀県に高速ブリスター包装ラインを建設すると発表しました。これは自動充填仕上げ生産施設に追加される予定です。

日本のCDMO（受託開発・製造機関）市場レポートハイライト：

• 2022年の売上高シェアはAPI製品が81.0%で最大。製品セグメントは原薬と医薬品に分けられます。
• 用途別では、商業セグメントが2022年に88.0%の最大収益シェアを占めました。これはジェネリック医薬品に対する需要の高まりによるもので、慢性疾患の負担が大きいことも成長の一因となっています。
• がん分野は、予測期間中にCAGR 6.4%の最速を記録すると予測されています。これは、国内でのがん患者数の増加により、新しいがん治療薬の需要が向上しているためです。
• 2020年11月、WuXi AppTecは細胞・遺伝子治療プラットフォームが提供するサービスを拡大しました。同プラットフォームは、細胞・遺伝子治療薬の開発、製造、導入をより迅速かつ高い予測可能性で行うことができるようになっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 日本のCDMO（受託開発・製造機関）の市場変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 普及と成長の見通しマッピング
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因分析
• 日本のCDMO（受託開発・製造機関）市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 日本CDMO（受託開発・製造機関）：製品別推定・動向分析

• 日本のCDMO（受託開発・製造機関）市場：重要なポイント
• 日本のCDMO（受託開発・製造機関）市場：動向と市場シェア分析、2022年および2030年
• API
  • API市場推計・予測、2018年から2030年まで
  • タイプ
  • 合成
  • 薬剤
  • 製造業
• 医薬品
  • 医薬品市場推計・予測、2018年から2030年まで
  • 経口固形投与量
  • 半固体投与量
  • 液体投与量
  • その他

第5章 日本のCDMO（受託開発・製造機関）：ワークフロー別推定・動向分析

• 日本のCDMO（受託開発・製造機関）市場：重要なポイント
• 日本のCDMO（受託開発・製造機関）市場：動向と市場シェア分析、2022年および2030年
• 臨床
• 商業

第6章 日本のCDMO（受託開発・製造機関）：用途別推定・動向分析

• 日本のCDMO（受託開発・製造機関）市場：重要なポイント
• 日本のCDMO（受託開発・製造機関）市場：動向と市場シェア分析、2022年および2030年
• オンコロジー
• ホルモン
• 緑内障
• 循環器疾患
• 糖尿病
• その他

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 市場参入企業の分類

List of Tables

• Table 1 List of Abbreviations
• Table 2 Japan contract development and manufacturing organization market, by product, 2018 - 2030 (USD Million)
• Table 3 Japan contract development and manufacturing organization market, by workflow, 2018 - 2030 (USD Million)
• Table 4 Japa contract development and manufacturing organization market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Japan contract development and manufacturing organization: Market outlook
• Fig. 9 Japan contract development and manufacturing organization: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Japan contract development and manufacturing organization market driver impact
• Fig. 15 Japan contract development and manufacturing organization market restraint impact
• Fig. 16 Japan contract development and manufacturing organization market strategic initiatives analysis
• Fig. 17 Japan contract development and manufacturing organization market: Product movement analysis
• Fig. 18 Japan contract development and manufacturing organization market: Product outlook and key takeaways
• Fig. 19 API market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Type market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Antibody drug conjugate (ADC) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Solid market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Liquid market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Drug market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Innovative market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Generic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Continuous manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Batch manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Drug product market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Oral solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Semi-solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Liquid dose market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Japan contract development and manufacturing organization market: Workflow movement analysis
• Fig. 42 Japan contract development and manufacturing organization market: Workflow outlook and key takeaways
• Fig. 43 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Japan contract development and manufacturing organization market: Application movement analysis
• Fig. 46 Japan contract development and manufacturing organization market: Application outlook and key takeaways
• Fig. 47 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Hormonal market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Japan Contract Development And Manufacturing Organization Market Growth & Trends:

The Japan contract development and manufacturing organization market size is expected to reach USD 19.5 billion by 2030, registering a CAGR of 5.9% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The main drivers of this market are rising investment by contract development and manufacturing organizations (CDMOs) for capacity expansion, a high geriatric population and growing disease burden in Japan, and low costs associated with outsourcing drug manufacturing and development services.

The COVID-19 pandemic boosted the demand for the CDMO market. Several CDMOs in Japan had tried to improve their capability by expanding their facilities even during the pandemic. For instance, in August 2020, Bushu Pharmaceuticals expanded its facility in the Misato plant in Japan to be dedicated to the storage of temperature-controlled sterile drugs and biologics. Similarly, in July 2020, CMIC Group established a new facility in Japan dedicated to processing development and GMP manufacturing of antibody drugs. Such initiatives by CDMOs in the country are expected to have a positive impact on the market.

The market players are continuously engaging in major strategic initiatives like expanding their facilities, collaborating, partnerships, new service launches, and mergers & acquisitions. For instance, in May 2020, Catalent, a market leader in clinical supply services, announced plans to buy a clinical packaging facility from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan. By making this purchase, a new clinical GMP production and distribution hub will be created to assist clinical research. Furthermore, in July 2022, Catalent announced that it would be constructing a high-speed blister packaging line in Shiga, Japan. This will be in addition to its automated fill-and-finish production facility.

Japan Contract Development And Manufacturing Organization Market Report Highlights:

• The API product segment accounted for the largest revenue share of 81.0% in 2022. The product segment is divided into API and drug product
• Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
• The oncology segment is anticipated to register the fastest CAGR of 6.4% during the forecast period, due to the growing number of cancer cases in the country which is improving the demand for new cancer therapeutics
• In November 2020, WuXi AppTec expanded its services offered by Cell & Gene Therapy Platform. The platform is now capable of developing, manufacturing, and introducing cell and gene therapies faster and with greater predictability

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Workflow
  • 1.1.3. Application
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Workflow
  • 2.2.3. Application
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Japan Contract Development and Manufacturing Organization Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Japan Contract Development and Manufacturing Organization Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Japan Contract Development and Manufacturing Organization: Product Estimates & Trend Analysis

• 4.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
• 4.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. API
  • 4.3.1. API market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.3.2. Type
    • 4.3.2.1. Type market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2.2. Traditional active pharmaceutical ingredient (traditional API)
    • 4.3.2.2.1. Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2.3. Highly potent active pharmaceutical ingredient (HP-API)
    • 4.3.2.3.1. Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2.4. Antibody drug conjugate (ADC)
    • 4.3.2.4.1. Antibody drug conjugate (ADC) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2.5. Others
    • 4.3.2.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.3.3. Synthesis
    • 4.3.3.1. Synthesis market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3.2. Synthetic
    • 4.3.3.2.1. Synthetic market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3.3. Solid
    • 4.3.3.3.1. Solid market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3.4. Liquid
    • 4.3.3.4.1. Liquid market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3.5. Biotech
    • 4.3.3.5.1. Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.3.4. Drug
    • 4.3.4.1. Drug market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.4.2. Innovative
    • 4.3.4.2.1. Innovative market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.4.3. Generic
    • 4.3.4.3.1. Generic market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.3.5. Manufacturing
    • 4.3.5.1. Manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.5.2. Continuous manufacturing
    • 4.3.5.2.1. Continuous manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.5.3. Batch manufacturing
    • 4.3.5.3.1. Batch manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Drug Product
  • 4.4.1. Drug product market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Oral solid dose
    • 4.4.2.1. Oral solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Semi-solid dose
    • 4.4.3.1. Semi-solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Liquid dose
    • 4.4.4.1. Liquid dose market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Japan Contract Development and Manufacturing Organization: Workflow Estimates & Trend Analysis

• 5.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
• 5.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Clinical
  • 5.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Commercial
  • 5.4.1. Commercial market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Japan Contract Development and Manufacturing Organization: Application Estimates & Trend Analysis

• 6.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
• 6.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Oncology
  • 6.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Hormonal
  • 6.4.1. Hormonal market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Glaucoma
  • 6.5.1. Glaucoma market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Cardiovascular Disease
  • 6.6.1. Cardiovascular disease market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Diabetes
  • 6.7.1. Diabetes delivery market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Market Participant Categorization
  • 7.2.1. CORDENPHARMA INTERNATIONAL
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. WuXi AppTec
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Cambrex Corporation
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Recipharm AB
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Lonza
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Catalent, Inc.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Laboratory Corporation of America Holdings
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Thermo Fisher Scientific, Inc
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Samsung BioLogics
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies U.S.A.)
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. SUMITOMO CHEMICAL COMPANY, LIMITED
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. CMIC HOLDINGS Co., LTD
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives
  • 7.2.13. Bushu Pharmaceuticals LTD.
    • 7.2.13.1. Company overview
    • 7.2.13.2. Financial performance
    • 7.2.13.3. Product benchmarking
    • 7.2.13.4. Strategic initiatives
  • 7.2.14. NIPRO
    • 7.2.14.1. Company overview
    • 7.2.14.2. Financial performance
    • 7.2.14.3. Product benchmarking
    • 7.2.14.4. Strategic initiatives